

JAN. 13. 2005 9:51AM AVENTIS US PAT DEPT  
TO: US USPTO GENERAL

RECEIVED  
CENTRAL FAX CENTER

NO. 1350 P. 1

JAN 13 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/674,480	
	Filing Date	September 30, 2003	
	First Named Inventor	Scott KLEIN et al.	
	Art Unit	1625	
	Examiner Name	CHANG, Celia	
Total Number of Pages in This Submission	3	Attorney Docket Number	USA2797 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm Name	AVENTIS PHARMACEUTICALS INC.
Signature	
Printed name	Joseph ROSSI
Date	January 13, 2005
Reg. No.	47038

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306; Total No. of Pages Transmitted: 3)	
Signature	
Typed or printed name	Paul Irvine
Date	January 13, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JAN. 13. 2005 9:52AM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 1350 P. 2

USA2797 US CNT

JAN 13 2005

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KLEIN, et al.**

Examiner: C. Chang

Art Unit: 1625

Application No.: 10/674,480

Filed: September 30, 2003

Title: **PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES**

TELEFAX CERTIFICATE  
I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on


January 13, 2005  
Date of Transmission

Signature 

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

This paper is in response to the Notice of Non-Compliant Amendment dated December 15, 2004 ("the Notice") and, therefore, is supplemental to Applicants' Reply in response to the Office Action dated June 9, 2004 ("the Action") in connection with the above-identified patent application. In compliance with the species election/restriction requirement set forth in the Action, Applicants elect the species N-(4-phenyl)-benzoyl-2-(R)-(3-(N-aminoiminomethyl)-(1,2,5,6-tetrahydropyridylmethyl))-3-(R)-methyl  $\beta$ -alanine methyl ester



which is the subject of Example 2 at page 48 of Applicants' specification.

Applicants believe that the foregoing constitutes a complete and full response to the Office Action dated June 9, 2004 and the Notice of Noncompliance dated December 15, 2004. Applicants respectfully submit that this application is now in condition for allowance. Accordingly, an indication of allowability and an early Notice of Allowance are respectfully requested.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Joseph D. Rossi, Registration No. 47,038  
Attorney for Applicant

Dated: January 13, 2005

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-3410  
Telefax: 908-231-2626  
Docket No. USA2797 US CNT